相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
Paulus Kirchhof et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study
Anton Pottegard et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2018)
Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants The Stockholm Experience
Tomas Forslund et al.
STROKE (2018)
Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database
Rebecca S. Bejhed et al.
ANNALS OF PHARMACOTHERAPY (2016)
Different risk factors for bleeding and discontinuation between dabigatran and rivaroxaban
Masami Nishino et al.
JOURNAL OF CARDIOLOGY (2016)
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
EP van Puijenbroek et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2002)
分享论文
